Karyopharm Current Deferred Revenue vs Long Term Debt Total Analysis

KPTI Stock

USD 0.85 0.07 8.97%

Karyopharm Therapeutics financial indicator trend analysis is infinitely more than just investigating Karyopharm Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Karyopharm Therapeutics is a good investment. Please check the relationship between Karyopharm Therapeutics Current Deferred Revenue and its Long Term Debt Total accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Current Deferred Revenue vs Long Term Debt Total

Current Deferred Revenue vs Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Karyopharm Therapeutics Current Deferred Revenue account and Long Term Debt Total. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Karyopharm Therapeutics' Current Deferred Revenue and Long Term Debt Total is 0.4. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Long Term Debt Total in the same time period over historical financial statements of Karyopharm Therapeutics, assuming nothing else is changed. The correlation between historical values of Karyopharm Therapeutics' Current Deferred Revenue and Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Karyopharm Therapeutics are associated (or correlated) with its Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt Total has no effect on the direction of Current Deferred Revenue i.e., Karyopharm Therapeutics' Current Deferred Revenue and Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

0.4

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Long Term Debt Total

Most indicators from Karyopharm Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Karyopharm Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.The Karyopharm Therapeutics' current Enterprise Value is estimated to increase to about 1.1 B, while Selling General Administrative is projected to decrease to under 67.5 M.

	2021	2022	2023	2024 (projected)
Gross Profit	206.4M	151.9M	141.1M	148.1M
Total Revenue	209.8M	157.1M	146.0M	153.3M

Gross Profit Total Revenue

Karyopharm Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Common Stock Total Equity	Retained Earnings Total Equity
Total Assets		0.5	0.63	0.09	0.74	0.44	0.16	-0.74	0.39	0.74	0.48	0.44	0.37	0.98	0.74	0.66	0.57	0.88	0.67	0.48	0.99	0.33	0.63	-0.5	0.57	-0.78
Other Current Liab	0.5		0.86	-0.66	0.54	0.64	0.57	-0.81	-0.2	0.43	0.27	0.68	0.21	0.39	0.78	0.84	0.79	0.67	0.86	0.41	0.47	-0.21	0.03	-0.87	0.84	-0.78
Total Current Liabilities	0.63	0.86		-0.47	0.63	0.65	0.52	-0.83	0.07	0.46	0.29	0.58	0.14	0.55	0.83	0.75	0.76	0.75	0.82	0.38	0.61	0.14	0.25	-0.76	0.83	-0.81
Total Stockholder Equity	0.09	-0.66	-0.47		-0.05	-0.21	-0.81	0.57	0.53	0.16	0.22	-0.34	-0.23	0.17	-0.48	-0.67	-0.45	-0.29	-0.68	-0.31	0.08	0.66	0.52	0.77	-0.66	0.53
Property Plant And Equipment Net	0.74	0.54	0.63	-0.05		0.33	0.38	-0.67	0.36	0.31	0.36	0.24	-0.13	0.68	0.68	0.55	0.61	0.77	0.58	0.33	0.73	0.34	0.44	-0.39	0.67	-0.68
Current Deferred Revenue	0.44	0.64	0.65	-0.21	0.33		0.07	-0.47	0.18	0.49	0.66	0.74	0.52	0.32	0.46	0.47	0.76	0.5	0.47	-0.08	0.37	0.21	0.2	-0.54	0.36	-0.48
Net Debt	0.16	0.57	0.52	-0.81	0.38	0.07		-0.72	-0.2	-0.28	-0.13	0.07	0.07	0.1	0.69	0.68	0.35	0.49	0.73	0.56	0.18	-0.28	-0.08	-0.65	0.8	-0.67
Retained Earnings	-0.74	-0.81	-0.83	0.57	-0.67	-0.47	-0.72		-0.09	-0.41	-0.27	-0.46	-0.36	-0.67	-0.97	-0.94	-0.7	-0.92	-0.97	-0.66	-0.74	0.09	-0.22	0.88	-0.94	0.99
Accounts Payable	0.39	-0.2	0.07	0.53	0.36	0.18	-0.2	-0.09		0.17	0.33	-0.33	-0.05	0.4	0.25	-0.18	-0.1	0.22	-0.1	0.11	0.36	0.78	0.63	0.25	0.03	-0.07
Cash	0.74	0.43	0.46	0.16	0.31	0.49	-0.28	-0.41	0.17		0.31	0.6	0.41	0.75	0.38	0.46	0.52	0.5	0.43	0.13	0.74	0.13	0.31	-0.39	0.27	-0.45
Non Current Assets Total	0.48	0.27	0.29	0.22	0.36	0.66	-0.13	-0.27	0.33	0.31		0.51	0.44	0.36	0.25	0.21	0.37	0.43	0.18	-0.02	0.36	0.33	0.47	-0.25	0.07	-0.34
Non Currrent Assets Other	0.44	0.68	0.58	-0.34	0.24	0.74	0.07	-0.46	-0.33	0.6	0.51		0.58	0.34	0.32	0.64	0.8	0.48	0.57	-0.07	0.4	-0.22	-0.02	-0.68	0.31	-0.53
Other Assets	0.37	0.21	0.14	-0.23	-0.13	0.52	0.07	-0.36	-0.05	0.41	0.44	0.58		0.31	0.25	0.5	0.38	0.41	0.43	0.11	0.33	-0.24	0.03	-0.52	0.11	-0.43
Cash And Short Term Investments	0.98	0.39	0.55	0.17	0.68	0.32	0.1	-0.67	0.4	0.75	0.36	0.34	0.31		0.68	0.59	0.46	0.81	0.6	0.5	0.99	0.36	0.66	-0.39	0.5	-0.7
Common Stock Shares Outstanding	0.74	0.78	0.83	-0.48	0.68	0.46	0.69	-0.97	0.25	0.38	0.25	0.32	0.25	0.68		0.84	0.59	0.87	0.9	0.72	0.73	0.08	0.36	-0.78	0.94	-0.93
Non Current Liabilities Total	0.66	0.84	0.75	-0.67	0.55	0.47	0.68	-0.94	-0.18	0.46	0.21	0.64	0.5	0.59	0.84		0.76	0.84	0.99	0.55	0.66	-0.32	0.04	-0.95	0.86	-0.95
Other Current Assets	0.57	0.79	0.76	-0.45	0.61	0.76	0.35	-0.7	-0.1	0.52	0.37	0.8	0.38	0.46	0.59	0.76		0.7	0.75	-0.03	0.55	-0.06	-0.06	-0.75	0.65	-0.73
Other Stockholder Equity	0.88	0.67	0.75	-0.29	0.77	0.5	0.49	-0.92	0.22	0.5	0.43	0.48	0.41	0.81	0.87	0.84	0.7		0.86	0.58	0.87	0.07	0.37	-0.75	0.79	-0.95
Total Liab	0.67	0.86	0.82	-0.68	0.58	0.47	0.73	-0.97	-0.1	0.43	0.18	0.57	0.43	0.6	0.9	0.99	0.75	0.86		0.59	0.67	-0.24	0.09	-0.94	0.92	-0.97
Property Plant And Equipment Gross	0.48	0.41	0.38	-0.31	0.33	-0.08	0.56	-0.66	0.11	0.13	-0.02	-0.07	0.11	0.5	0.72	0.55	-0.03	0.58	0.59		0.5	-0.1	0.41	-0.46	0.62	-0.61
Total Current Assets	0.99	0.47	0.61	0.08	0.73	0.37	0.18	-0.74	0.36	0.74	0.36	0.4	0.33	0.99	0.73	0.66	0.55	0.87	0.67	0.5		0.3	0.59	-0.48	0.58	-0.77
Short Term Debt	0.33	-0.21	0.14	0.66	0.34	0.21	-0.28	0.09	0.78	0.13	0.33	-0.22	-0.24	0.36	0.08	-0.32	-0.06	0.07	-0.24	-0.1	0.3		0.77	0.44	-0.13	0.1
Property Plant Equipment	0.63	0.03	0.25	0.52	0.44	0.2	-0.08	-0.22	0.63	0.31	0.47	-0.02	0.03	0.66	0.36	0.04	-0.06	0.37	0.09	0.41	0.59	0.77		0.14	0.09	-0.23
Net Tangible Assets	-0.5	-0.87	-0.76	0.77	-0.39	-0.54	-0.65	0.88	0.25	-0.39	-0.25	-0.68	-0.52	-0.39	-0.78	-0.95	-0.75	-0.75	-0.94	-0.46	-0.48	0.44	0.14		-0.83	0.89
Common Stock Total Equity	0.57	0.84	0.83	-0.66	0.67	0.36	0.8	-0.94	0.03	0.27	0.07	0.31	0.11	0.5	0.94	0.86	0.65	0.79	0.92	0.62	0.58	-0.13	0.09	-0.83		-0.89
Retained Earnings Total Equity	-0.78	-0.78	-0.81	0.53	-0.68	-0.48	-0.67	0.99	-0.07	-0.45	-0.34	-0.53	-0.43	-0.7	-0.93	-0.95	-0.73	-0.95	-0.97	-0.61	-0.77	0.1	-0.23	0.89	-0.89

Click cells to compare fundamentals

Karyopharm Therapeutics Account Relationship Matchups

Karyopharm Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	295.0M	313.1M	305.3M	358.2M	240.4M	238.3M
Other Current Liab	41.4M	(6.4M)	67.5M	57.4M	59.7M	62.7M
Total Current Liabilities	46.4M	297K	73.7M	65.9M	69.5M	73.0M
Total Stockholder Equity	49.8M	50.5M	(79.7M)	(16.7M)	(136.2M)	(129.4M)
Property Plant And Equipment Net	3.0M	2.2M	1.6M	7.4M	4.9M	3.0M
Current Deferred Revenue	2.3M	297K	69.1M	25.1M	28.8M	15.7M
Net Debt	(19.0M)	32.0M	(21.2M)	37.8M	124.8M	131.0M
Retained Earnings	(873.3M)	(1.1B)	(1.2B)	(1.3B)	(1.5B)	(1.4B)
Accounts Payable	985K	4.5M	1.6M	2.8M	3.1M	3.5M
Cash	128.9M	85.9M	190.5M	135.2M	52.2M	101.6M
Non Current Assets Total	21.3M	23.5M	47.2M	31.4M	6.5M	6.2M
Non Currrent Assets Other	16.2M	(2.9M)	44.9M	23.4M	1.6M	1.6M
Other Assets	714K	34.3M	45.6M	633K	1.0	0.95
Cash And Short Term Investments	264.0M	273.5M	228.6M	278.0M	192.1M	201.8M
Common Stock Shares Outstanding	62.0M	72.0M	75.2M	81.9M	114.2M	119.9M
Liabilities And Stockholders Equity	295.0M	313.1M	305.3M	358.2M	240.4M	238.3M
Non Current Liabilities Total	245.2M	262.2M	385.0M	374.8M	307.2M	322.5M
Other Current Assets	1.5M	559K	20.4M	20.9M	11.8M	6.1M
Other Stockholder Equity	923.1M	1.1B	1.1B	1.3B	1.4B	748.9M
Total Liab	245.2M	262.5M	385.0M	374.8M	376.6M	395.5M
Property Plant And Equipment Gross	13.7M	11.6M	1.6M	1.1M	11.4M	12.0M
Total Current Assets	273.7M	289.5M	258.1M	326.8M	233.9M	215.6M
Accumulated Other Comprehensive Income	(37K)	518K	191K	(638K)	(161K)	(169.1K)
Short Term Debt	1.6M	1.9M	4.6M	5.7M	6.6M	8.5M
Property Plant Equipment	3.0M	2.2M	1.6M	1.1M	1.3M	2.2M
Net Tangible Assets	49.8M	50.5M	(79.7M)	(16.7M)	(15.0M)	(14.2M)
Long Term Debt	109.9M	117.9M	169.3M	170.1M	170.9M	179.5M
Retained Earnings Total Equity	(873.3M)	(1.1B)	(1.2B)	(1.3B)	(1.2B)	(1.1B)
Short Term Investments	133.1M	163.3M	38.2M	142.8M	139.2M	115.6M
Capital Surpluse	923.1M	1.1B	1.1B	1.3B	1.5B	824.8M
Other Liab	8.5M	75.8M	144.6M	215.7M	248.0M	260.4M
Net Invested Capital	159.6M	168.5M	169.3M	170.1M	34.7M	33.0M
Net Working Capital	232.2M	216.3M	201.9M	284.3M	164.4M	233.5M
Short Long Term Debt Total	111.5M	119.8M	169.3M	173.0M	177.0M	162.5M

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:

How To Invest In Karyopharm

Details

Is Karyopharm Stock a good investment?

Details

What is Karyopharm Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.05)

Revenue Per Share

1.247

Quarterly Revenue Growth

0.077

Return On Assets

(0.34)

Return On Equity

(8.91)

The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Karyopharm Current Deferred Revenue vs Long Term Debt Total Analysis

Current Deferred Revenue vs Long Term Debt Total

Current Deferred Revenue vs Long Term Debt Total Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Long Term Debt Total

Karyopharm Therapeutics fundamental ratios Correlations

Karyopharm Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Karyopharm Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Retained Earnings Total Equity	+ 0.99	Retained Earnings
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.98	Total Assets
Common Stock Total Equity	+ 0.94	Common Stock Shares Outstanding

Retained Earnings Total Equity	- 0.97	Total Liab
Total Liab	- 0.97	Retained Earnings
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Retained Earnings Total Equity	- 0.95	Other Stockholder Equity
Retained Earnings Total Equity	- 0.95	Non Current Liabilities Total
Net Tangible Assets	- 0.95	Non Current Liabilities Total